Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
Heather Han(Moffitt Cancer Center), Véronique Dièras(Institut Curie), Mark E. Robson(Cornell University), Markéta Palácová(Masaryk University), P. Kelly Marcom(Duke University), Agnes Jager(Erasmus MC Cancer Institute), Igor Bondarenko(Dnipro State Medical University), Dennis L. Citrin(Midwestern Regional Medical Center), Mario Campone(Institut de Cancérologie de l'Ouest), Melinda L. Telli(Stanford University), Susan M. Domchek(University of Pennsylvania), Michael Friedländer(Prince of Wales Hospital), Bella Kaufman(Sheba Medical Center), Judy E. Garber(Dana-Farber Cancer Institute), Yaroslav Shparyk, Ewa Chmielowska, Erik Jakobsen(Vejle Sygehus), Virginia Kaklamani(The University of Texas at San Antonio Health Science Center), William J. Gradishar(Northwestern University), Christine K. Ratajczak(AbbVie (United States)), Caroline Nickner(AbbVie (United States)), Qiuyue Qin(AbbVie (United States)), Jane Qian(AbbVie (United States)), Stacie Peacock Shepherd(AbbVie (United States)), Steven J. Isakoff(Massachusetts General Hospital), Shannon Puhalla(UPMC Hillman Cancer Center)
Cited by 206Open Access
Abstract
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler et al.|Journal of Clinical Oncology|2014|1.7k